• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Bruker Corporation filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    12/9/25 10:10:52 AM ET
    $BRKR
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $BRKR alert in real time by email
    8-K
    0001109354false0001109354brkr:SixPointThreeSevenFivePercentageMandatoryConvertiblePreferredStockSeriesAMember2025-12-092025-12-090001109354us-gaap:CommonStockMember2025-12-092025-12-0900011093542025-12-092025-12-09

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 8-K

    CURRENT REPORT

    Pursuant to Section 13 or 15(d)

    of The Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): December 9, 2025

     

    BRUKER CORPORATION

    (Exact name of registrant as specified in its charter)

     

     

     

     

     

    Delaware

    000-30833

    04-3110160

    (State or other jurisdiction of

    (Commission

    (I.R.S. Employer

    incorporation)

    File number)

    Identification No.)

     

    40 Manning Road

    Billerica, MA 01821

    (Address of principal executive offices) (Zip Code)

     

    (978) 663-3660

    (Registrant’s telephone number, including area code)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

    Title of Each Class

    Trading Symbol(s)

    Name of Each Exchange on Which Registered

    Common Stock, $0.01 par value per share

    BRKR

    The Nasdaq Global Select Market

    6.375% Mandatory Convertible Preferred Stock, Series A, $0.01 par value per share

     

    BRKRP

     

     

    The Nasdaq Global Select Market

     

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

    Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     


     

    Section 5 - Corporate Governance and Management

    Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

    (d) Election of New Director

     

    On December 8, 2025, the Board of Directors (the “Board”) of Bruker Corporation (the “Company”) approved an increase in the number of directors to expand the size of the Board by one director to a total of eleven directors, with such additional director assigned to Class III, and appointed Jack J. Phillips to fill the newly created vacancy on the Board, effective as of January 1, 2026. Mr. Phillips will initially serve as a director until the 2027 Annual Meeting of Stockholders.

     

    Mr. Phillips’ compensation for his services as a director will be consistent with that of the other non-employee directors of the Company, as described in the Company’s definitive proxy statement with respect to the 2025 Annual Meeting of Stockholders, filed with the Securities and Exchange Commission on April 11, 2025. There are no other arrangements or understandings between Mr. Phillips and any other person pursuant to which he was elected as a director, and Mr. Phillips is not a party to any transaction with the Company that would require disclosure under Item 404(a) of Regulation S-K.

     

    The Company will file an amended Form 8-K to disclose Mr. Phillips’ committee assignments once determined.

    A copy of the press release announcing Mr. Phillips’ appointment is attached to this report as Exhibit 99.1.

     

    Section 9 – Financial Statements and Exhibits

     

    Item 9.01. Financial Statements and Exhibits.

     

    (d)

    Exhibits.

    Number

    Description

    99.1

    Press release dated December 8, 2025.

     

    104

     

    Cover Page Interactive Data File (embedded within the Inline XBRL document).


     

     

     

     


     

    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

    BRUKER CORPORATION
    (Registrant)

     Date: December 9, 2025

    By:

    /s/ GERALD N. HERMAN

    Gerald N. Herman

    Executive Vice President and Chief Financial Officer

     

     

     


    Get the next $BRKR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BRKR

    DatePrice TargetRatingAnalyst
    12/10/2025$60.00Peer Perform → Outperform
    Wolfe Research
    12/9/2025$40.00Sell
    Goldman
    11/20/2025$60.00Buy
    Rothschild & Co Redburn
    5/22/2025$40.00Buy → Neutral
    Citigroup
    12/19/2024$72.00Buy
    Guggenheim
    12/10/2024$66.00Neutral
    UBS
    12/5/2024$60.00Sell → Neutral
    Goldman
    10/15/2024$75.00Overweight
    Barclays
    More analyst ratings

    $BRKR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EXEC VP&PRES BRUKER NANO INC. Munch Mark exercised 2,000 shares at a strike of $22.19 and sold $98,400 worth of shares (2,000 units at $49.20) (SEC Form 4)

    4 - BRUKER CORP (0001109354) (Issuer)

    1/16/26 4:15:05 PM ET
    $BRKR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    EXEC VP&PRES BRUKER NANO INC. Munch Mark exercised 7,000 shares at a strike of $22.19 and sold $385,000 worth of shares (7,000 units at $55.00) (SEC Form 4)

    4 - BRUKER CORP (0001109354) (Issuer)

    1/13/26 4:15:06 PM ET
    $BRKR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form 3 filed by new insider Phillips Jack

    3 - BRUKER CORP (0001109354) (Issuer)

    1/9/26 6:19:27 PM ET
    $BRKR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $BRKR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Bruker Announces $500 Million in Multi-Year Orders from Two Global Healthcare Companies for Supply of High-Performance Superconductors for MRI

    The Bruker Energy & Supercon Technologies (BEST) division, a segment of Bruker Corporation (NASDAQ:BRKR), today announced two multi-year supply agreements for Bruker's latest superconductors, which are used by global radiology companies to build their next generations of magnetic resonance imaging (MRI) magnets. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260109007299/en/Typical niobium-titanium-copper composite superconductors suitable for MRI magnets. The combined order value of the two agreements is approximately $500 million in expected future BEST revenues, with different agreement duration periods, with one agreement ex

    1/9/26 7:00:00 AM ET
    $BRKR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Bruker Consolidates Ownership of TOFWERK in Expansion of Mass Spectrometry Portfolio into New Applied Markets

    TOFWERK is a profitable innovator in compact, ultra-fast time-of-flight (TOF) mass spectrometry for real-time air and semiconductor cleanroom monitoring, food, flavors & fragrances markets, and FIB-TOF accessories for electron microscopes The ultra-sensitive Vocus™ TOF-MS is customizable for real-time air and cleanroom monitoring applications Microwave-induced plasma (MIP)-TOF systems with atto-to-femtogram detection limits for real-time quantification of trace elements and metals Proprietary flow tube-based VUV CI sources for positive and negative trace organics, inorganics and PFAS contaminants Focused Ion Beam (FIB)-TOF accessories for scanning electron microscopes Bruker

    1/8/26 7:00:00 AM ET
    $BRKR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Bruker Corporation to Present at the J.P. Morgan Healthcare Conference

    Bruker Corporation (NASDAQ:BRKR) announced today it will participate in the 45th annual J.P. Morgan Healthcare Conference in San Francisco. Senior leadership will present on behalf of the Company on Monday, January 12th, 2026 at 9:00 AM Pacific Standard Time. A live audio webcast of the presentation will be available on the Investor Relations section of the Company's website at https://ir.bruker.com. A replay of the presentation will be posted in the "Events & Presentations" section of the Bruker Corporation Investor Relations website after the event and will be available for 30 days following the presentation. About Bruker Corporation – Leader of the Post-Genomic Era (NASDAQ:BRKR) Br

    1/7/26 4:01:00 PM ET
    $BRKR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $BRKR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Bruker upgraded by Wolfe Research with a new price target

    Wolfe Research upgraded Bruker from Peer Perform to Outperform and set a new price target of $60.00

    12/10/25 9:02:11 AM ET
    $BRKR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Goldman initiated coverage on Bruker with a new price target

    Goldman initiated coverage of Bruker with a rating of Sell and set a new price target of $40.00

    12/9/25 8:43:14 AM ET
    $BRKR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Rothschild & Co Redburn initiated coverage on Bruker with a new price target

    Rothschild & Co Redburn initiated coverage of Bruker with a rating of Buy and set a new price target of $60.00

    11/20/25 8:06:38 AM ET
    $BRKR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $BRKR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    PRESIDENT & CEO Laukien Frank H bought $100,043 worth of shares (2,608 units at $38.36), increasing direct ownership by 0.01% to 38,462,171 units (SEC Form 4)

    4 - BRUKER CORP (0001109354) (Issuer)

    6/9/25 4:15:11 PM ET
    $BRKR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Chief Accounting Officer Bures Thomas bought $23,698 worth of shares (500 units at $47.40), increasing direct ownership by 17% to 3,472 units (SEC Form 4)

    4 - BRUKER CORP (0001109354) (Issuer)

    3/11/25 4:11:27 PM ET
    $BRKR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    PRESIDENT & CEO Laukien Frank H bought $1,018,330 worth of shares (20,000 units at $50.92), increasing direct ownership by 0.05% to 38,459,563 units (SEC Form 4)

    4 - BRUKER CORP (0001109354) (Issuer)

    2/19/25 4:23:26 PM ET
    $BRKR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $BRKR
    SEC Filings

    View All

    Bruker Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure

    8-K - BRUKER CORP (0001109354) (Filer)

    1/12/26 12:00:24 PM ET
    $BRKR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Bruker Corporation filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - BRUKER CORP (0001109354) (Filer)

    12/9/25 10:10:52 AM ET
    $BRKR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form 144 filed by Bruker Corporation

    144 - BRUKER CORP (0001109354) (Subject)

    12/1/25 4:14:06 PM ET
    $BRKR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $BRKR
    Leadership Updates

    Live Leadership Updates

    View All

    Solis Agrosciences Names Crystal Winkeler Chief Business Officer to Drive Commercial Growth

    ST. LOUIS, April 23, 2025 (GLOBE NEWSWIRE) -- Solis Agrosciences, the trusted partner for high-quality AgTech research services, announced that it has hired Crystal Winkeler as Chief Business Officer. Winkeler will join Solis on May 1 to drive the company's commercial team and help lead efforts to develop and acquire new offerings. "Solis has assembled an impressive team, offerings, and customer base," said Winkeler. "I am thrilled to join the business at this important growth stage." "Crystal is a proven talent who is confident, capable, and credible in front of customers and stakeholders," said Charlie Bolten, CEO of Solis Agrosciences. "She is a huge addition and will help drive our c

    4/23/25 6:15:00 AM ET
    $BRKR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Bruker Appoints Laura Francis to its Board of Directors

    Bruker Corporation (NASDAQ:BRKR) today announced that its Board of Directors has appointed Laura Francis to serve on its board as an independent director, effective as of February 18, 2025. Ms. Francis is also expected to join Bruker's Audit Committee as a financial expert after Bruker's annual shareholder meeting at the end of May 2025. Laura Francis is the Chief Executive Officer and a Board Member of SI-BONE, Inc. (NASDAQ:SIBN), a medical device company solving musculoskeletal disorders of the sacropelvic anatomy. She was previously the Chief Financial Officer and Chief Operating Officer of the company. Prior to joining SI-BONE, Ms. Francis held other executive and leadership roles with

    2/21/25 8:00:00 AM ET
    $BRKR
    $PGNY
    $SIBN
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Misc Health and Biotechnology Services
    Health Care

    Biognosys and Alamar Biosciences Forge Strategic Partnership in Proteomics to Advance Biopharma and Precision Medicine Research

    Strategic partnership expands Biognosys' services to include Alamar's NULISA assays as well as joint scientific research in biofluid-based proteomicsComplementary value of Biognosys' DIA-MS unbiased proteomics platform and Alamar's game-changing immunoassay platforms to be presented at the AACR 2024 Annual Meeting ZURICH, Switzerland and FREMONT, Calif., April 04, 2024 (GLOBE NEWSWIRE) -- Biognosys, a global leader in mass spectrometry-based proteomics, and Alamar Biosciences, Inc., a company powering precision proteomics to enable the earliest detection of disease, are pleased to announce a strategic partnership aimed at advancing scientific discovery in the field of biofluid proteomic

    4/4/24 8:11:00 AM ET
    $BRKR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $BRKR
    Financials

    Live finance-specific insights

    View All

    Bruker Consolidates Ownership of TOFWERK in Expansion of Mass Spectrometry Portfolio into New Applied Markets

    TOFWERK is a profitable innovator in compact, ultra-fast time-of-flight (TOF) mass spectrometry for real-time air and semiconductor cleanroom monitoring, food, flavors & fragrances markets, and FIB-TOF accessories for electron microscopes The ultra-sensitive Vocus™ TOF-MS is customizable for real-time air and cleanroom monitoring applications Microwave-induced plasma (MIP)-TOF systems with atto-to-femtogram detection limits for real-time quantification of trace elements and metals Proprietary flow tube-based VUV CI sources for positive and negative trace organics, inorganics and PFAS contaminants Focused Ion Beam (FIB)-TOF accessories for scanning electron microscopes Bruker

    1/8/26 7:00:00 AM ET
    $BRKR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Bruker Announces Quarterly Common Stock Dividend and Preferred Stock Dividend

    Bruker Corporation (NASDAQ:BRKR, BRKRP)) today announced that its Board of Directors ("Board") has approved payment of a quarterly cash dividend in the amount of $0.05 per share on the Company's common stock, par value $0.01 per share (the "Common Stock Dividend"). The Common Stock Dividend will be paid on January 2, 2026 to stockholders of record as of December 8, 2025. The Board also approved payment of a quarterly cash dividend in the amount of $3.6745 per share on the Company's 6.375% Mandatory Convertible Preferred Stock, Series A, par value $0.01 per share (the "Mandatory Convertible Preferred Stock Dividend"). The Mandatory Convertible Preferred Stock Dividend will be paid on Decemb

    11/4/25 4:01:00 PM ET
    $BRKR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Bruker Reports Third Quarter 2025 Financial Results

    Q3 2025 revenues of $860.5 million, down 0.5% year-over-year (yoy), down 4.5% organically Q3 2025 GAAP diluted loss per share $(0.41); non-GAAP diluted earnings per share (EPS) $0.45 Updated FY2025 guidance: Revenue $3.41 to $3.44 billion; reported growth of 1-2% yoy, organic decline of 4-5% Non-GAAP EPS $1.85 to $1.90   Bruker Corporation (NASDAQ:BRKR) today announced financial results for the three and nine months ended September 30, 2025. Frank H. Laukien, Bruker's President and CEO, commented: "In the third quarter, we were encouraged by our mid-single digit percentage organic bookings growth year-over-year, with a Scientific Instruments segment book-to-bill ratio

    11/3/25 7:00:00 AM ET
    $BRKR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $BRKR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Bruker Corporation

    SC 13G/A - BRUKER CORP (0001109354) (Subject)

    11/14/24 1:28:29 PM ET
    $BRKR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Amendment: SEC Form SC 13G/A filed by Bruker Corporation

    SC 13G/A - BRUKER CORP (0001109354) (Subject)

    11/13/24 6:01:26 PM ET
    $BRKR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Amendment: SEC Form SC 13G/A filed by Bruker Corporation

    SC 13G/A - BRUKER CORP (0001109354) (Subject)

    11/12/24 11:54:03 AM ET
    $BRKR
    Biotechnology: Laboratory Analytical Instruments
    Industrials